1921
Volume 93, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

We describe the results from a human clinical trial of a dengue virus serotype-1, purified-inactivated vaccine (DENV-1 PIV) adjuvanted with aluminum hydroxide. This first-in-man, Phase 1, open-label clinical trial consisted of two groups of flavivirus-naïve healthy adult volunteers that received two intramuscular vaccine doses of either 2.5 μg or 5 μg of DENV-1 PIV administered on days 0 and 28. Following vaccination, both vaccine doses exhibited an acceptable safety profile with minimal injection site and systemic reactions. By study day 42, 2 weeks following the second vaccine dose, all volunteers in both vaccine groups developed serum-neutralizing antibodies against DENV-1. Additional testing using an enzyme-linked immunosorbent assay demonstrated induction of a humoral immune response following both vaccine doses. The DENV-1 PIV was safe and immunogenic in a small number of volunteers supporting development and further testing of a tetravalent DENV PIV formulation.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.14-0819
2015-09-02
2017-09-19
Loading full text...

Full text loading...

/deliver/fulltext/14761645/93/3/454.html?itemId=/content/journals/10.4269/ajtmh.14-0819&mimeType=html&fmt=ahah

References

  1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GRW, Simmons CP, Scott TW, Farrar JJ, Hay SI, , 2013. The global distribution and burden of dengue. Nature 496: 504507.[Crossref]
  2. WHO, 2012. Dengue and Severe Dengue. Fact Sheet No. 117. Available at: http://www.who.int/mediacentre/factsheets/fs117/en/index.html. Accessed January 2012.
  3. Centers for Disease Control and Prevention, 1994. Dengue fever among U.S. military personnel–Haiti. JAMA 273: 1415.
  4. Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, Mahoney RT, Wang DNC, Meltzer MI, , 2004. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 22: 12751280.[Crossref]
  5. Thomas SJ, , 2011. The necessity and quandaries of dengue vaccine development. J Infect Dis 203: 299303.[Crossref]
  6. WHO, 2009. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. New edition. Available at: http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf.
  7. Thomas SJ, , 2014. Developing a dengue vaccine: progress and future challenges. Ann N Y Acad Sci 1323: 140159.[Crossref]
  8. Wallace D, Canouet V, Garbes P, Wartel TA, , 2013. Challenges in the clinical development of a dengue vaccine. Current Opinion in Virology 3: 352356.[Crossref]
  9. Halstead SB, , 2013. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 31: 45014507.[Crossref]
  10. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramirez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Montoya MC, Supelano MC, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F, , 2014. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Eng J Med 372: 113123.[Crossref]
  11. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithurn P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A, , 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomized, observer-masked, placebo-controlled trial. Lancet 384: 13581365.[Crossref]
  12. Coller BAG, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH, , 2011. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 29: 72677275.[Crossref]
  13. Putnak R, Barvir D, Burrous J, Dubois D, Dandrea V, Hoke C, Sadoff J, Eckels K, , 1996. Development of a purified, inactivated dengue 2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus macaques. J Infect Dis 174: 11761184.[Crossref]
  14. Putnak JR, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, Bignami G, Houng HS, Chen RC, Barvir DA, Seriwatana J, Cayphas S, Garcon N, Gheysen D, Kanesa-Thasan N, McDonell M, Humphreys T, Eckels KH, Prieels JP, Innis BL, , 2005. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23: 44424452.[Crossref]
  15. Simmons M, Porter KR, Hayes CG, Vaughn DW, Putnak R, , 2006. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 80: 95779585.[Crossref]
  16. Simmons M, Burgess T, Lynch J, Putnak R, , 2010. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 396: 280288.[Crossref]
  17. Lyons A, Kanesa-thasan N, Kuschner RA, Eckels KH, Putnak R, Sun W, Burge R, Towle AC, Wilson P, Tauber E, Vaughn DW, , 2007. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 25: 34453453.[Crossref]
  18. Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, Schranz S, Jong E, Klingler A, Dewasthaly S, Klade CS, , 2007. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomized controlled trial. Lancet 370: 18471853.[Crossref]
  19. Duggan ST, Plosker GL, , 2009. Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO]. Drugs 69: 115122.[Crossref]
  20. Kunz C, , 2003. TBE vaccination and the Austrian experience. Vaccine 21: S150S155.
  21. Fischer M, Yendell SJ, Rollin PE, , 2013. Tickborne Encephalitis. CDC Health Information for International Travel 2014: The Yellow Book. 60.1:304.
  22. Eckels KH, Putnak RP, , 2003. Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines. Adv Virus Res 61: 395418.[Crossref]
  23. Yauch LE, Shresta S, , 2014. Dengue virus vaccine development. Adv Virus Res 88: 315372.[Crossref]
  24. Zompi S, Montoya M, Pohl MO, Balmaseda A, Harris E, , 2012. Dominant cross- reactive B cell response during secondary acute dengue virus infection in humans. PLoS NTD 6: 114.
  25. Puschnik A, Lau L, Cromwell EA, Balmaseda A, Zompi S, , 2013. Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans. PLoS Negl Trop Dis 7: e2274.[Crossref]
  26. Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, Putnak R, Toussaint J-F, Sun W, Bauer K, Gibbons RV, Innis BL, , 2013. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg 88: 7388.[Crossref]
  27. Breukels MA, Joi-van der Zijde EM, van Tol MJD, Rijkers GT, , 2002. Concentration and avidity of anti-Haemophilus influenzae type B (Hib) antibodies in serum samples obtained from patients for whom Hib vaccination failed. Clin Infect Dis 34: 191197.[Crossref]
  28. Zlamy M, Wurzner R, Holzmann H, Brandstatter A, Jeller V, Zimmerhackl LB, Prelog M, , 2010. Antibody dynamics after tick-borne encephalitis and measles-mumps-rubella vaccination in children post early thymectomy. Vaccine 28: 80538060.[Crossref]
  29. Mercader S, Garcia P, Bellini WJ, , 2012. Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination settings. Clin Vaccine Immunol 19: 18101817.[Crossref]
  30. Boxus M, Lockman L, Fochesato M, Lorin C, Thomas F, Giannini SL, , 2014. Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule. Vaccine 32: 32323236.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.14-0819
Loading
/content/journals/10.4269/ajtmh.14-0819
Loading

Data & Media loading...

Supplementary Data

Supplementary PDF

  • Received : 18 Dec 2014
  • Accepted : 12 May 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error